Pu X, Xiao Z, Li J, Wu Z, et al. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial. Lung Cancer 2024;191:107538.
PMID: 38552544